Pharmaceutical Executive April 11, 2024
Ellenor discusses key points from the recent SCOPE presentation.
There is a strong reported appetite for hybrid or fully decentralized clinical trials (DCTs) across industry stakeholders from patients to regulators and sponsors. In 2020, the DCT and digital boom coincided with the COVID-19 pandemic as the industry found operational solutions to travel restrictions and closures. At ICON, we saw an increase in the number of requests from sponsors for DCT proposals at that time, though there has been a slight taper in DCT uptake in recent years as we collectively ‘return to normal’ and the pressure to implement decentralized components slackened.
Despite the dip, DCT is here to stay. In fact, it is evolving for novel uses deployed in fit-for-purpose,...
Today's Sponsors
Today's Sponsor